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A harmonized meta-knowledgebase of clinical
interpretations of somatic genomic variants
in cancer
Alex H. Wagner 1, Brian Walsh 2, Georgia Mayfield2, David Tamborero3,4, Dmitriy Sonkin 5,
Kilannin Krysiak 1, Jordi Deu-Pons6,7, Ryan P. Duren8, Jianjiong Gao 9, Julie McMurry2,
Sara Patterson10, Catherine del Vecchio Fitz11, Beth A. Pitel12, Ozman U. Sezerman13, Kyle Ellrott2,
Jeremy L. Warner 14, Damian T. Rieke 15, Tero Aittokallio 16,17, Ethan Cerami11, Deborah I. Ritter18,19,
Lynn M. Schriml20, Robert R. Freimuth 12, Melissa Haendel 2,21, Gordana Raca22,23, Subha Madhavan24,
Michael Baudis25, Jacques S. Beckmann 26, Rodrigo Dienstmann27, Debyani Chakravarty9,
Xuan Shirley Li8, Susan Mockus 10, Olivier Elemento28, Nikolaus Schultz9, Nuria Lopez-Bigas3,6,7,
Mark Lawler29, Jeremy Goecks2, Malachi Griffith 1 ✉, Obi L. Griffith 1 ✉, Adam A. Margolin2 and
Variant Interpretation for Cancer Consortium*
Precision oncology relies on accurate discovery and interpretation of genomic variants, enabling individualized diagnosis, prognosis and therapy selection. We found that six prominent somatic cancer variant knowledgebases were highly disparate in
content, structure and supporting primary literature, impeding consensus when evaluating variants and their relevance in a
clinical setting. We developed a framework for harmonizing variant interpretations to produce a meta-knowledgebase of 12,856
aggregate interpretations. We demonstrated large gains in overlap between resources across variants, diseases and drugs as
a result of this harmonization. We subsequently demonstrated improved matching between a patient cohort and harmonized
interpretations of potential clinical significance, observing an increase from an average of 33% per individual knowledgebase
to 57% in aggregate. Our analyses illuminate the need for open, interoperable sharing of variant interpretation data. We also
provide a freely available web interface (search.cancervariants.org) for exploring the harmonized interpretations from these
six knowledgebases.

P

recision oncology—in which treatment is informed by the
mutational profile of a cancer—requires concise, standardized
and searchable clinical interpretations of detected variants.
Interpretations of biomarker–disease associations can be diagnostic,
prognostic, therapeutic (predictive of favorable or adverse response
to therapy) and/or predisposing (germline variants that increase
risk of developing cancer). Many have curated the biomedical literature to collect and formalize these interpretations into knowledgebases1–12. These isolated efforts have resulted in disparate knowledge
representation, and exchange of these biomarker–disease associations remains a difficult challenge13. Consequently, stakeholders
interested in the effects of somatic cancer variants are faced with
the following trade-off: (1) reconciling multiple representations and
interpretations across knowledgebases; or (2) potentially omitting

clinically significant interpretations that are not universally captured. Manual aggregation of information across knowledgebases
to interpret the variant profile for each patient is an unsustainable
approach at scale. Moreover, the lack of an integrated resource has
precluded the ability to easily assess the current state of precision
treatment options. Published reports14–17 have relied on individual,
often highly discordant knowledgebases. Interoperability and automated aggregation are required to make a comprehensive approach
to cancer precision medicine tractable and to establish consensus
across knowledgebases.
The current diversity and number of ‘knowledge silos’ and the
associated difficulties of coordinating these disparate knowledgebases have led to an international effort to maximize genomic
data sharing18,19. The Global Alliance for Genomics and Health
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(GA4GH) has emerged as an international cooperative project to
accelerate the development of approaches for responsible, voluntary
and secure sharing of genomic and clinical data20,21. The Variant
Interpretation for Cancer Consortium (VICC; cancervariants.org)
is a Driver Project of GA4GH, established to co-develop standards
for genomic data sharing (https://www.ga4gh.org/how-we-work/
driver-projects/ga4gh.org/howwework/driver-projects.html).
Specifically, the VICC is a consortium of clinical variant interpretation experts addressing the challenges of representing and sharing
curated interpretations across the cancer research community.
Somatic variants in cancer-relevant genes are evaluated from
multiple partially overlapping perspectives (Supplementary Note).
The Association for Molecular Pathology, the American Society of
Clinical Oncology and the College of American Pathologists (AMP/
ASCO/CAP) have published structured somatic variant clinical
interpretation guidelines that specifically address diagnostic, prognostic and therapeutic implications22. These guidelines do not provide systematic and comprehensive procedures to classify somatic
variant oncogenicity, as has been published in the American College
of Medical Genetics and Genomics (ACMG)/AMP guidelines23 for
pathogenicity interpretation of germline variants.
Another common difference between somatic and germline classification is the frequent use of variant representations
that are defined by multiple alternative genomic alterations,
including protein variants such as NP_004295.2:p.F1174L (ALK
F1174L; caused by either NC_000002.11:g.29443695G>T or
NC_000002.11:g.29443695G>C), and categorical variants24, such
as ‘loss-of-function mutations’ or ‘activating mutations’ (the use of
the word ‘mutations’ in these variant names is a somatic-specific
nomenclature that is common across these knowledgebases). This
represents an important distinction from the interpretation of
germline variants, which are typically described by singular and
specific DNA variants, and only rarely in broader terms. A primary
challenge of this work was to handle the complexity of these somatic
variant representations.
We leveraged the VICC member expertise to aggregate cancer
variant interpretations from six distinguished constituent knowledgebases: the Cancer Genome Interpreter Cancer Biomarkers
Database (CGI), Clinical Interpretation of Variants in Cancer
(CIViC), Jackson Laboratory Clinical Knowledgebase (JAX-CKB),
MolecularMatch (MMatch), OncoKB and the Precision Medicine
Knowledgebase (PMKB) (Supplementary Table 1)1,5,9–11. From a
larger survey of published and available knowledgebases of clinical interpretations of genomic variants (Supplementary Table 1),
these knowledgebases were selected for their similarity in somatic
disease focus. The institutions leading each constituent knowledgebase agreed upon a core set of principles describing minimal data
licensing and structure requirements (http://cancervariants.org/
principles/ and Supplementary Note).
Our cooperative effort developed a framework for structuring
and harmonizing clinical interpretations across these knowledgebases. Specifically, we defined key elements of variant interpretations (genes, variants, diseases, drugs and evidence), developed
strategies for harmonization and implemented this framework to
consolidate interpretations into a single, harmonized meta-knowledgebase (freely available at search.cancervariants.org).

Analysis
knowledgebase-specific (shorthand, internal identifier) representations (Fig. 1). Representations of an element could vary within
a knowledgebase, such as with the use of shorthand for diseases,
including both standardized representations (for example, ‘CLL’ and
‘ALL’ are both listed synonyms in the NCI Thesaurus27) and internal
representations (for example, ‘G’ (glioma), ‘L’ (lung cancer) or ‘OV’
(ovarian cancer)).
We harmonized variant interpretations from each of these
knowledgebases by mapping all data elements in each knowledgebase to established standards and ontologies describing genes,
variants, diseases and drugs (Fig. 1 and Supplementary Note).
Briefly, genes were harmonized using the HGNC gene symbols.
Variants were harmonized through a combination of knowledgebase-specific rules, matching to the Catalog of Somatic Mutations
in Cancer (COSMIC)3, and use of the ClinGen Allele Registry
(reg.clinicalgenome.org)28. Diseases were harmonized using the
European Bioinformatics Institute (EBI) Ontology Lookup Service
(OLS; www.ebi.ac.uk/ols/index) to retrieve Disease Ontology (DO)
terms and identifiers. Drugs were harmonized through queries to
the Mychem.info API (mychem.info), PubChem29 and ChEMBL30.
Details for each of these harmonization strategies are described in
Methods and Extended Data Fig. 1.
Due to the knowledgebase-specific nature of describing an
interpretation evidence level (Fig. 1), harmonization required
manual mapping of evidence levels to a common standard. The
AMP/ASCO/CAP somatic classification guidelines were released
after (and partially informed by) the design of the VICC knowledgebases. These guidelines are compatible with (but not identical
to) the existing evidence levels of these knowledgebases. We constructed a mapping of evidence levels provided by each knowledgebase to the evidence levels constituting AMP/ASCO/CAP tier I and
II variants (Table 1).

Aggregating and structuring interpretation knowledge. A review
of the constituent somatic knowledgebases of the VICC (Fig. 1 and
Supplementary Table 1)1,5,9–11 showed dramatic differences in the
components of variant interpretations, which were often a mixture
of concepts with standardized (such as Human Gene Nomenclature
Committee (HGNC) gene symbols25, Human Genome Variation
Society (HGVS) variant nomenclature26), externally referenced
(identified elements of an established ontology or database) or

The landscape of variant interpretation knowledge. The metaknowledgebase v.0.10 release contained 12,856 harmonized interpretations (hereafter referred to as the core dataset; Methods)
supported by 4,354 unique publications for an average of 2.95
interpretations per publication. Notably, 83% of all publications
were referenced by only one knowledgebase, and only one publication31 was referenced across all six knowledgebases (Extended Data
Fig. 2a). Gene symbols were almost universally provided; the few
interpretations lacking gene symbols (<0.01%) were structural variants that were not associated with an individual gene. In contrast
to publications, the genes curated by the cancer variant interpretation community are much more frequently observed in multiple
knowledgebases. We observed that 23% of genes (97/415) with at
least one interpretation were present in at least half of the knowledgebases, compared to only 5% of publications (203/4,354; odds
ratio, OR = 1.6 × 10−1, P = 4.7 × 10−34; Fisher’s exact test, two-sided;
Extended Data Fig. 2b).
Variants had little overlap across the core dataset (Fig. 2a). Of
the constituent 3,439 unique variants, 76.6% were described by
only one knowledgebase, and <10% were observed in at least three
(Fig. 2b). This lack of overlap was partially due to the complexity of
variant representation. For example, the representation of an ERBB2
variant as described in nomenclature defined by the HGVS26 is
NP_004439.2:p.Y772_A775dup, and yet it is referenced in multiple
different forms in the biomedical literature. p.E770delinsEAYVM32,
p.M774insAYVM33 and p.A775_G776insYVMA34 all describe an
identical protein kinase domain alteration, although they appear
to identify different variants (Fig. 2c). Despite having a standard
representation by the HGVS guidelines, these alternative forms continue to appear in the literature. Consequently, a researcher looking
to identify a specific match to NP_004439.2:p.E770delinsEAYVM
may find no direct matches, although several exist under various
alternate representations. This component of variant harmonization
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Skin melanoma, predicts sensitivity,
vemurafenib
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trametinib + dabrafenib (combination)
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13 interpretations
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Results

Fig. 1 | Creation of a harmonized meta-knowledgebase. Six variant interpretation knowledgebases of the VICC (top panel) and representative symbolic
interpretations from each (colored columns) are illustrated. Interpretations are split across five different elements: gene, variant, disease, drugs and
evidence, and are colored to indicate their originating knowledgebase. Reference-linked elements correspond to unique identifiers from established
authorities for that element (for example, the use of Entrez or Ensembl gene identifiers). Standardized elements correspond to immediately recognizable
formats or descriptions of elements, but are not linked to an authoritative definition. Resource-specific elements are described by terminology unique to
the knowledgebase. These elements are each harmonized (bottom left panel) to a common reference standard (shown here is the use of HGNC for genes,
ChEMBL for drugs, AMP/ASCO/CAP guidelines for evidence, Disease Ontology for diseases and ClinGen Allele Registry for variants). This harmonized
meta-knowledgebase allows for querying across interpretations from each of the constituent VICC knowledgebases (bottom right panel, example query
BRAF V600E), returning aggregated results, which are categorized and sorted by evidence level.

Table 1 | Mapping knowledgebase-specific evidence codes to AMP/ASCO/CAP guidelines
Evidence
level

Defining characteristics

Level A
(tier I)

CIViC

OncoKB

JAX-CKB

CGI

MMatch

PMKB

Evidence from professional guidelines or FDA-approved Level A
therapies relating to a biomarker and disease.

Level
1/2A /R1

Guideline/FDA
approved

Clinical
practice

Level 1A

Tier 1

Level B
(tier I)

Evidence from clinical trials or other well-powered
studies in clinical populations, with expert consensus.

Level 3A

Phase III

Clinical trials
III–IV

Level 1B

Level C
(tier II)

Evidence for therapeutic predictive markers from case Predictive
studies, or other biomarkers from several small studies. level C
Also, evidence for biomarker therapeutic predictions
for established drugs for different indications.

Level 2B,
level 3B

Clinical study/
phase I/phase II

Clinical trials
I–II, case
reports

Level 2C

Level D
(tier II)

Preclinical findings or case studies of prognostic or
diagnostic biomarkers. Also includes indirect findings.

Phase 0,
preclinical

Preclinical
data

Level 2D

Level B

Nonpredictive Level 4
level C/level
D/level E

Tier 2

was addressed through the use of the ClinGen Allele Registry
(Methods). Some differences in the scale and structure of
these knowledgebases may be attributed to curation strategies
(Supplementary Note).
To illustrate the challenges of searching across multiple variant
representations, we surveyed all interpretations describing the previously discussed ERBB2 variant (NP_004439.2:p.Y772_A775dup)
using the web interfaces provided by each knowledgebase (Table 2
and Supplementary Table 2). Each knowledgebase represented this

variant differently. Two did not have specific interpretations for
this variant, although they did have relevant categorical variants
(for example, ‘exon 20 insertions’; Table 2). Most of the knowledgebases had a single internal representation of the variant, although
the majority of these representations did not match across knowledgebases. The evidence describing these interpretations varied
considerably in form, as each used knowledgebase-specific nomenclature (for example, evidence described as ‘level 3A’ in OncoKB is
equivalent to ‘level 1B’ from MolecularMatch, or ‘level B’ from
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Fig. 2 | Representation of genomic variants across interpretation knowledgebases. a, UpSet plot46 of variants across six cancer variant interpretation
knowledgebases (KBs). Sets of variant interpretation knowledgebases with shared variants are indicated by colored dots in the lower panel, with color
indicating set size (for example, yellow dots indicate only the single designated knowledgebase in the set, green dots indicate two knowledgebases in
the set, etc.). Objects are attributed to the largest containing set; thus, a variant described by all six knowledgebases is attributed to the dark blue set
with eight variants. b, Pie chart visualizing overall uniqueness of variants, with categories indicating the number of knowledgebases describing each
variant. Nearly 77% of variants are unique across the knowledgebases, with only 0.2% ubiquitously represented. The eight variants present in all six
knowledgebases are listed on the right. c, A comparison of element uniqueness across knowledgebases. Despite having the greatest degree of overlap
across all elements, approximately 61% of genes are unique across the knowledgebases. Literature cited to support interpretations has the smallest degree
of overlap across all elements, with 83% of publications remaining unique across the knowledgebases. *Drugs are not evaluated for PMKB, which does
not formally represent this concept. d, Multiple syntactically valid representations of an identical protein product can lead to confusion in describing the
change in the literature and in variant databases. The wild-type protein sequence (dark blue with orange lettering) is represented for ERBB2 (top). Two
(of many) possible representations of an inframe insertion (orange with dark blue lettering) are shown (bottom). A nonstandard HGVS expression
describes a five-amino-acid insertion replacing one glutamate residue (middle). At the bottom, the HGVS standard representation shows an identical
protein product from a four-amino-acid duplication. A search for one representation against a database with another (nonoverlapping) representation may
lead to omission of a clinically relevant finding.

CIViC; Tables 1 and 2). Of the 19 unique publications describing
the collected evidence, only three were observed in more than
one knowledgebase, and none were observed in more than two.
Interestingly, the curated interpretations from these shared publications varied by knowledgebase in disease scope (‘advanced solid
tumor’ compared to ‘non-small cell lung cancer’ (NSCLC)35; ‘breast
cancer and NSCLC’ compared to ‘cancer’36). A review of the interpretations showed some that are present in most of the knowledgebases
(for example, ‘use of afatinib, trastuzumab or neratinib in NSCLC’;
Table 2), and others that are present in only one or two (for example,
‘use of lapatinib in lung adenocarcinoma’ and ‘use of afatinib and
rapamycin in combination in NSCLC’; Table 2). Importantly, this
includes sparse interpretations that describe conflicting evidence
(for example, ‘no benefit from neratinib in NSCLC’; Table 2) or negative evidence (for example, ‘does not support sensitivity/response
to dacomitinib in NSCLC’; Table 2). Collectively, these data illustrate the diversity in knowledgebase structure, content, terminology

and curation methodology. Consequently, utilizing a subset of these
knowledgebases would likely result in differing interpretations
before the harmonization performed in this study.
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Harmonization improves consensus across interpretations. To
test the effect of our harmonization methods on generating consensus, we evaluated the overlap of unique interpretation elements
from each knowledgebase of the core dataset in comparison to
unharmonized (but aggregated) data (Methods). As noted above,
genes from each resource used HGNC gene symbols, resulting in
very little gain from harmonization; 45% of genes across knowledgebases overlapped without harmonization, compared to 46%
with harmonization. This is in contrast to variants (8% overlapping unharmonized, 26% overlapping harmonized), diseases (27%
unharmonized, 34% harmonized) and drugs (20% unharmonized,
36% harmonized) (Supplementary Table 3). None of the evidence
levels were consistent across resources when unharmonized, and all
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Table 2 | Comprehensive assessment of the NP_004439.2:p.Y772_A775dup variant across clinical interpretation knowledgebases
Resource

ERBB2 variant
name

Evidence

Document ID

Interpretation

CIViC

M774INSAYVM

Level B, 2-star

PMID: 25899785

Does not support sensitivity/response to dacomitinib in NSCLC

M774INSAYVM

Level C, 4-star PMID: 26559459

Supports sensitivity/response to afatinib in lung adenocarcinoma

M774INSAYVM

Level C, 3-star PMID: 22325357

Supports sensitivity/response to afatinib in lung adenocarcinoma

M774INSAYVM

Level C, 3-star PMID: 25789838

Supports sensitivity/response to trastuzumab emtansine in lung
adenocarcinoma

M774INSAYVM

Level D, 3-star PMID: 19122144

Supports sensitivity/response to afatinib and rapamycin
(combination) in NSCLC

Kinase domain
mutation

Level C, 4-star PMID: 26598547

Supports sensitivity/response to trastuzumab in lung
adenocarcinoma

Kinase domain
mutation

Level C, 3-star PMID: 22325357

Supports sensitivity/response to afatinib in lung adenocarcinoma

Exon 20 insertions

Level 4

10.1158/1538-7445.
AM2016-2644

Supports response to AP32788 in NSCLC

Oncogenic
mutations

Level 3A

PMID: 23220880

Supports response to neratinib in breast cancer and NSCLC

inframe insertion
A775YVMA

Early trials

10.1200/
JCO.2017.35.15_
suppl.8510

Responsive to ado-trastuzumab emtansine in lung cancer

inframe insertion
A775YVMA

Early trials

10.1158/1538-7445.
AM2017-CT001

Responsive to neratinib in cancer

proximal exon 20

Early trials

PMID: 26598547

Responsive to afatinib, neratinib, lapatinib or trastuzumab in lung
adenocarcinoma

OncoKB

CGI

10.1158/1538-7445.
AM2017-CT001

10.1200/
JCO.2017.35.15_
suppl.9071
PMKB

exon(s) 20
insertion

Tier 2

PMID: 22761469

Associated with sensitivity to some ERBB2 inhibitors in lung
adenocarcinoma

Y772_A775dup

Clinical study

PMID: 26964772

Conflicting response to afatinib in lung adenocarcinoma

Y772_A775dup

Phase II

PMID: 29420467

Predicted sensitive to neratinib in Her2-receptor-negative breast
cancer

Y772_A775dup

Phase II

PMID: 29420467

Predicted resistant to neratinib in urinary bladder cancer and NSCLC

Y772_A775dup

Preclinical

PMID: 26545934

Sensitive to afatinib in lung cancer

Y772_A775dup

Preclinical

PMID: 26545934

No benefit to gefitinib in lung cancer

Y772_A775dup

Preclinical

PMID: 28363995

Sensitive to neratinib in advanced solid tumor

exon 20 insertion

Clinical study

PMID: 28167203

Predicted sensitive to afatinib or trastuzumab in NSCLC

exon 20 insertion

Clinical study

PMID: 26964772

Predicted sensitive to afatinib in lung adenocarcinoma

exon 20 insertion

Phase II

PMID: 29420467

Predicted sensitive to neratinib in Her2-receptor-negative breast
cancer

exon 20 insertion

Phase II

PMID: 29420467

No benefit to neratinib in NSCLC

exon 20 insertion

Preclinical

10.1158/1538-7445.
AM2016-2644

Sensitive to AP32788 in advanced solid tumor

Y772_A775dup

Level 1B

PMID: 22325357,
26964772

Confers sensitivity to afatinib in patients with neoplasm of lung

Y772_A775dup

Level 2C

PMID: 26598547

Confers sensitivity to trastuzumab in patients with neoplasm of lung

Y772_A775dup

Level 2D

PMID: 22325357

Confers sensitivity to afatinib in patients with neoplasm of breast

A775_
G776insYVMA

Level 1A

PMID: 26559459,
22325357, 26545934

Confers sensitivity to afatinib in patients with neoplasm of lung

A775_
G776insYVMA

Level 2C

PMID: 23610105,
26964772, 22908275

Confers sensitivity to afatinib in patients with neoplasm of breast

A775_
G776insYVMA

Level 2D

PMID: 17311002,
22908275

Confers sensitivity to neratinib in patients with neoplasm of breast

PMID: 16818618
PMID: 25152623

JAX-CKB

MolecularMatch
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are consistent with a common standard (Table 1) after harmonization, which is a primary contribution of this work.
Notably, in some cases, harmonization dramatically increased
the number of elements to be considered. For example, CGI had an
increase in variant count from 283 (unharmonized) to 1,600 (harmonized) due to the expansion of ambiguous categorical variants
(for example, ‘oncogenic mutation’) to the set of variants considered
oncogenic by CGI (through extraction and mapping of the CGI
Catalog of Validated Oncogenic Mutations). As mentioned above,
the PMKB does not have a formalized ‘drug’ field for interpretations,
so there is no reasonably accessible data for aggregating or harmonizing drugs for that resource. Drugs and variants both had a relatively
greater benefit from normalization compared to the other interpretation elements, which was likely driven by the diverse and numerous synonymous representations of these concepts in use. While the
complexities of variant representation have been discussed above,
the complexity of drug labeling in these resources is driven by the
multiple synonyms given to drugs in their numerous formulations
and brands, which change relatively frequently over time.

Analysis
in the GENIE cohort, compared to the average 33% obtained when
using each constituent knowledgebase individually (Fig. 3f). We
observed that broadening the search scope to include any regional
match (Extended Data Fig. 4) increased the cohort coverage to 86%
of patients (compared to an average of 68% per individual knowledgebase). However, it is prudent to keep in mind that the increase
in matching percentage using regional match instead of exact match
would be partly due to nononcogenic passenger variants.
A key component in determining the clinical relevance of an
interpretation is whether the tumor type reported in the interpretation matches the patient’s tumor type (see ‘Defining characteristics’
in Table 1). Restricting patient search results to those interpretations that are of matching grouped disease terms (Extended Data
Fig. 4 and Supplementary Note) resulted in 29% of patients with at
least one clinical interpretation (compared to an average individual
knowledgebase match rate of 13%), and 18% of patients with at least
one tier I clinical interpretation (compared to an average 6% per
individual knowledgebase) (Fig. 3f). Patients with rare diseases were
disadvantaged in this analysis, as automated mapping of their disease terms to DO was less likely to succeed (Supplementary Note).
Allowing matching to any ancestor or descendant term and allowing partial variant overlaps improves matches to 60% (compared
to an average of 35% per individual knowledgebase). This broader
strategy, however, requires contextual re-evaluation of assigned
AMP/ASCO/CAP evidence levels, which are designated for a precise match to variant and disease context. Consequently, evidence
level or tier filtering can only be used with an exact search strategy.
We evaluated an alternative, highly permissive search strategy that
matches sample variants to any interpretation in the gene (Extended
Data Fig. 6). The resulting match profile across the knowledgebases
is comparable to findings from the overlapping variant strategy,
indicating that many of the commonly mutated genes have genelevel interpretations (which would be a match by either strategy).
A comparison of interpretations across the previously described
common cancers (with proportion >5% in Supplementary Table 5)
showed that the use of grouped terms instead of exact terms for
matching interpretations to patients’ cancers varies dramatically
by cancer type, with some cancers (for example, lung cancer and
melanoma) showing little increased interpretation breadth, while
others have enormous effect (for example, breast cancer and large
intestine cancer; Fig. 3g). This is primarily due to the specific nature
by which patients are classified with certain diseases, versus the
aggregate nature by which interpretations are ascribed to diseases.
Interestingly, 56% of GENIE patient samples (6,196/11,149) have
disease-matched interpretations across the frequently observed
cancers, compared to only 40% (5,430/13,724) of patient samples
across all other cancers (OR = 1.9, P = 3.9 × 10−140; Fisher’s exact test,
two-sided). These numbers are reduced to 44% (4,881/11,149) and
18% (2,438/13,724), respectively, when considering only tier I interpretations (OR = 3.6, P < 2.2 × 10−308; Fisher’s exact test, two-sided).

Harmonization increases findings of clinical significance.
Evaluation of patient variants for strong clinical significance
requires an assessment of these variants in the appropriate disease context. When grouped to the nearest top-level disease term
(Supplementary Table 4 and Supplementary Note), five major cancer group terms each accounted for over 5% of all interpretations in
the core dataset: lung cancer (24%), breast cancer (13%), hematologic cancer (11%), large intestine cancer (9%) and melanoma (6%)
(Fig. 3a and Supplementary Table 5). Notably, the most common
interpretations mirror top-level terms that have both high incidence
(Fig. 3b) and high mortality (Fig. 3c) as reported by the American
Cancer Society (Supplementary Table 6)37: lung cancer, breast cancer and hematologic cancer. The ‘large intestine cancer’ term contains numerous interpretations describing colorectal cancers, which
are closely related to colon cancer (a top-five cancer in both incidence and mortality; Supplementary Table 7). Evaluation of these
terms across the core dataset showed significant differences in the
distribution of common cancer types constituting each knowledgebase, illustrating the value of aggregating knowledgebases for a
more comprehensive landscape of interpretations (Extended Data
Fig. 3 and Supplementary Table 8).
To further test the value of harmonized interpretation knowledge,
we evaluated the 38,207 patients of the AACR Project Genomics
Evidence Neoplasia Information Exchange (GENIE)38. We first queried the 237,175 moderate- or high-impact variants from GENIE
using a broad search strategy (Methods and Extended Data Fig. 4).
Notably, 11% (4,355) of patients lacked any variants to search before
filtering on predicted impact, and 12% (4,543) after. This search
yielded 2,316,305 interpretation search results for an average of 9.8
interpretations per variant query. For a point mutation, these interpretations included matches to alternate alleles at the same position,
associated amino acid changes, the exon or functional domain or
gene-level interpretations such as overexpression, gain/loss-offunction or simply mutations. Restricting to a positional match (and
thus excluding gene-level interpretations; Extended Data Fig. 4)
showed an interpretation result set dominated by a few common
GENIE point mutations in variants each with a large number of
interpretations, including BRAF NP_004324.2:p.V600E, KRAS
NP_004976.2:p.G12 mutations and both NP_006209.2:p.E545K and
NP_006209.2:p.H1047R mutations in PIK3CA (Extended Data Fig.
5). This is congruent with our observation that the interpretations of
the core dataset for the most common diseases are highly focused on
these and other specific genes (Fig. 3d), including tier I interpretations (Fig. 3e). Examining our results at the patient level showed that
a focused, variant-level search resulted in at least one interpretation
(in any cancer type with any level of evidence) for 57% of patients

A resource for searching variant interpretation knowledge. We
have developed and hosted a public web interface for exploring the
VICC meta-knowledgebase, freely available at search.cancervariants.org. This interface retrieves the most recent data release from
an ElasticSearch index. Searching the knowledgebase is performed
by specifying filters for any term or entering free text or compound
(for example, and/or logic) queries in the search box at the top
of the page (Fig. 4a). Panels with data distribution visualizations
describe the current result set (Fig. 4b). These interactive panels
provide additional information about specific subsets and may be
used to create additional filters (for example, clicking on a level in
the ‘evidence_level’ panel filters results throughout the page to display only those interpretations with the designated evidence level).
This allows investigators to see the distribution of interpretations
by evidence level, disease, gene and drug, and to filter according
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Fig. 3 | Clinical interpretations of variants are defined by disease. a–c, Core dataset interpretations for top-level disease groups. Distinct diseases are
shown if the constituent interpretations for that disease account for at least 5% of the total dataset (a). Diseases accounting for at least 5% of cancer
incidence (b) and mortality (c) are also displayed. Approximately 8% of interpretations are categorized as benign neoplasms (dark gray; for example von
Hippel–Lindau disease). An additional 1% are categorized under high-level terms other than DOID:14566, disease of cellular proliferation. d,e, Heat map of
frequent gene–disease interpretations (d) and the related heat map limited to tier 1 interpretations (e). f, Percentage of Project GENIE cohort with at least
one interpretation from the indicated knowledgebase that matches patient variants (left group), patient variants and disease (center group) or patient
variants, disease and a tier I evidence level (right group). A broader search strategy (indicated by whisker bars; Extended Data Fig. 4) that allows for
regional variant matches (for example, gene level) and broader interpretation of disease terms (for example, DOID:162, cancer) nearly doubles the number
of patients with matching interpretations. These broader match strategies are incompatible with the ASCO/AMP/CAP evidence guidelines. g, Most
significant finding (by evidence level) across patient samples, by disease. Each column represents one of the common diseases indicated in a, and the
rows represent the evidence levels described in Table 1. Inner, light green circles (labeled Singular) indicate the proportion observed when matching patient
diseases to interpretations with the same disease ontology term. Outer, dark green circles (labeled Grouped) indicate the proportion observed when
matching patients to interpretations with ancestor or descendant terms that group to the same class of disease (Methods). Hem. cancer, hematological
cancer; Lrg. int. cancer, large intestine cancer.

to their interests. Tabulated results are provided at the bottom of
the page (Fig. 4c), and are expandable with all details, including
the (unharmonized) record provided by the original knowledgebase for each interpretation. These search tools are available via
both the web interface and an application programming interface
(API) search endpoint (Methods), in addition to a GA4GH beacon on beacon-network.org. Additionally, a Python interface and
analysis workbook have been developed to enable reproduction

(and additional exploration) of the data presented in this paper,
as well as full downloads of the underlying data (Methods). Usage
documentation and example queries for this resource may be found
at docs.cancervariants.org.
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Discussion

In this study, we aggregated, harmonized and analyzed clinical interpretations of cancer variants from six major knowledgebases1,5,9–11.
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Our analysis uncovered highly disparate content in curated knowledge, structure and primary literature across these knowledgebases.
Specifically, we evaluated the unique nature of the vast majority of
genomic variants reported across these knowledgebases and demonstrated the challenge of developing a consensus interpretation given
these disparities. These challenges are exacerbated by nonstandard
representations of clinical interpretations, in both the primary literature and curated knowledge of these resources. It is encouraging
that the curators of these knowledgebases have, without coordination, independently curated diverse literature and knowledge
sources. However, this reflects an enormous curation burden generated from the increasingly employed molecular characterizations of

patient tumors and the related expansion of the primary literature
describing them. Even at the gene level, for which there is the highest degree of overlap across any element of an interpretation, 61% of
genes with interpretations are observed in only one knowledgebase.
Our findings thus highlight the need for a cooperative, global effort
to curate comprehensive and thorough clinical interpretations of
somatic variants for robust practice of precision medicine.
We observed that harmonization improved concordance between
interpretation elements across resources (Supplementary Note), and
as a result we were able to achieve at least one specific (positionmatched) harmonized variant interpretation for 57% of the patients
in the GENIE cohort. In the most stringent searches, we required
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diversity of variant interpretations available across resources, leading to inconsistency in interpretation of cancer variants. We have
assembled a framework and recommendations for structuring and
harmonizing such interpretations, from which the cancer genomics community can improve consensus interpretation for cancer
patients. We have also developed and released open-source (MITlicensed) and freely available aggregated knowledge resources (web
application, data downloads and API) and associated analysis tools.
Our working group and open-source software development environment are open to all and we welcome participation from anyone
with an interest in learning about, utilizing, augmenting, improving
or proposing new directions for this community-based project, for
the benefit of cancer patients.

a precise variant match to a tier I interpretation also matching the
patient’s cancer; in these cases, 18% of the cohort had a finding of
strong clinical significance. Notably, these findings were substantially higher in patients with more common cancers, with 39% of the
common cancer samples variant matching at least one tier I interpretation, compared to 15% of other cancer samples. These findings
are concordant with observations of matched therapy rates in precision oncology trials, including 15% from IMPACT/COMPACT15,
11% from MSK-IMPACT14, 5% from the MD Anderson Precision
Medicine Study16 and 23% from the NCI-MATCH trials17.
Collectively, our results portray a confluence of knowledge
describing the most common genomic events relevant to the most
frequent cancers, with highly disparate knowledge describing less
frequent events in rare cancer types. The differing content of these
knowledgebases may be a result of research programs targeted at
frequent cancers, highlighting a need for a broader focus on less
common cancers. This sparse landscape of curated interpretation
knowledge is exacerbated by paucity in cross-references between
ontologies describing disease, highlighting the importance of bridging this gap39. Similarly, complexities in variant representation have
elucidated a need for sophisticated methods to harmonize genomic
variants; harmonization with the ClinGen Allele Registry28 is suited
to point mutations and indels, but the representation and harmonization of complex and nongenomic (for example, expression or
epigenetic) variants remains a challenge.
Our harmonized clinical interpretation meta-knowledgebase
represents a significant step forward in building consensus that
was previously unattainable due to a lack of harmonization services, such as the Allele Registry, and expert standards and guidelines, such as those recommended by AMP/ASCO/CAP. This
meta-knowledgebase serves as an open resource for evaluating
interpretations from institutions with distinct curation structure,
procedures and objectives. Potential uses include expert-guided
therapy matching, supporting FDA regulatory processes associated
with laboratory-developed genomic tests for guiding therapy and
identification of diseases and biomarkers that warrant future study.
The meta-knowledgebase web application is available at search.
cancervariants.org, with usage documentation and examples at
docs.cancervariants.org. The content of this meta-knowledgebase
is dynamic, as we routinely poll the constituent knowledgebases
for their associations between variants and clinical interpretations,
which primarily comprise predictions of somatic variant effect on
disease response to a therapy. Unlike the recently FDA-recognized
ClinGen Expert Curated Human Variant Data40,41, this resource
is not meant to be used to directly annotate clinical reports, but
rather to serve as a search tool for existing knowledge pertaining to
observed genomic variation.
While our initial efforts provide a structure by which variant
interpretation knowledgebases can contribute to a broader and
more consistent set of interpretations, much work remains to be
done. In particular, VICC members contribute to GA4GH Work
Streams to develop and integrate new and existing42–45 standards
for the representation of variant interpretations and the evidence
that describe them. Our web interface is being redesigned to a fullscale web service and user interface to concisely represent the most
relevant interpretations for one or more variants. Specifically, we
plan to add visual elements depicting the distribution of diseases
corresponding to a searched variant, search modes specific to user
intent (for example, disease-focused search, gene-focused search
or multivariant search) and restyled result summaries. These and
other planned changes are tracked on our central repository at git.
io/metakb (Supplementary Note for other planned improvements).
In conclusion, there is a great need for a collaborative effort
across institutions to build structured, harmonized representations
of clinical interpretations of cancer genomic variants to advance the
implementation of precision medicine. Our work has illustrated the
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Methods

Collecting cancer variant interpretation knowledge. OncoKB, the CGI and
JAX-CKB all contain complementary knowledge of variant oncogenicity. While
valuable, knowledge of a variant’s potential role in driving tumorigenesis is
structured differently than clinical interpretations of genomic variants, and is
therefore outside of the scope of this manuscript. While omitted from the analyses
presented in this paper, we do aggregate these annotations due to their potential
utility in clinical research. ClinGen, ACMG, AMP, ASCO, VICC and CAP are
working on developing guidelines to enable consistent and comprehensive
assessment of oncogenicity of somatic variants. In the future, variant oncogenicity
interpretations based on such guidelines can be incorporated into metaknowledgebases and should help to improve the harmonization of related
interpretations.
Exact code for collecting and harmonizing each of the VICC knowledgebases
may be found at https://github.com/ohsu-comp-bio/g2p-aggregator. The cancer
biomarker database from CGI was collected from the cgi_biomarkers_per_variant.
tsv file from the biomarkers download at https://www.cancergenomeinterpreter.
org/data/cgi_biomarkers_latest.zip. CIViC content was collected via the gene and
variant API endpoints documented online at https://docs.civicdb.org/en/latest/api.
html. JAX-CKB content of the publicly available 86 genes was collected from an
unpublished API endpoint (collecting code at https://github.com/ohsu-comp-bio/
g2p-aggregator/blob/v0.10/harvester/jax.py#L145-L147). MolecularMatch content
was collected via an authorized API key for use in the aggregated knowledgebase
(collecting code at https://github.com/ohsu-comp-bio/g2p-aggregator/blob/v0.10/
harvester/molecularmatch.py). OncoKB content was collected via a combination
of the levels, genes, variants and variants/lookup API endpoints documented at:
http://oncokb.org/#/dataAccess. PMKB content was provided as a JSON file by the
knowledgebase, which we are hosting at: https://s3-us-west-2.amazonaws.com/
g2p-0.7/unprocessed-files/pmkb_interpretations.json.
Harmonizing genes. Gene symbols were matched to the table of gene symbols
from HGNC, hosted at the EBI47: ftp://ftp.ebi.ac.uk/pub/databases/genenames/
new/json/non_alt_loci_set.json. This table was used to construct an ‘aliases’
table comprised of retired and alternate symbols for secondary lookup if the
interpretation gene symbol was not found among the primary gene symbols
from HGNC. If an alias used by a knowledgebase was shared between two genes,
omitted by the knowledgebase or failed to match either the primary or alias table,
the gene was omitted from the normalized gene field.
Harmonizing variants. Variants collected from each knowledgebase were
first evaluated for attributes specifying a precise genomic location, such as
chromosome, start and end coordinates, variant allele and an identifiable reference
sequence. Variant names were queried against the Catalog of Somatic Mutations
in Cancer (COSMIC)3 v.81 to infer these attributes in knowledgebases that did
not provide them. Custom rules were written to transform some types of variants
without clear coordinates (for example, amplifications) into gene coordinates. All
variants were then assembled into HGVS strings and submitted to the ClinGen
Allele Registry (http://reg.clinicalgenome.org) to obtain distinct, cross-assembly
allele identifiers, if available.
Harmonizing diseases. Diseases were matched to the DO48, through lookup
with the EBI OLS47, unless a preexisting ontology term for a different ontology
existed (98.7% of interpretations map to DO). We downloaded the March
2018 release of the TopNode terms from https://github.com/DiseaseOntology/
HumanDiseaseOntology/blob/master/src/ontology/subsets/TopNodes_
DOcancerslim.json and mapped our interpretation diseases to this list, assigning
each disease to its nearest TopNode ancestor (Supplementary Table 4 and
Supplementary Note). We assigned remaining interpretation diseases to the
nonspecific term of DOID:162 (cancer) if the disease was a descendant of this
term, but not a descendant of one of the TopNode terms.
Harmonizing drugs. Drug names were first queried against the biothings API49
for harmonization (documented at https://mychem.info/v1/api) and if not found
were subsequently queried against the PubChem Compounds29, PubChem
Substances and ChEMBL30 web services (see https://github.com/ohsu-comp-bio/
g2p-aggregator/blob/v0.10/harvester/drug_normalizer.py for details).
Harmonizing evidence level. Evidence levels were standardized to the AMP/
ASCO/CAP guidelines as outlined in Table 1.
Comprehensive evaluation of ERBB2 duplication. Public web portals for the
six VICC knowledgebases were manually searched for interpretations for variants
describing the alteration detailed in Fig. 2c. The MolecularMatch resource
changed its data access policy after peer review of this manuscript, and is no longer
accessible to the public. The web portals for the remaining resources are freely
available online without registration at the following URLs:
•
•
•

CGI: https://www.cancergenomeinterpreter.org/biomarkers
CIViC: https://civicdb.org/search/variants/
JAX-CKB: https://ckb.jax.org/geneVariant/find
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•
•

OncoKB: http://oncokb.org
PMKB: https://pmkb.weill.cornell.edu

Evaluating nonharmonized aggregate content. To evaluate the gains provided
by our harmonization methods, we collected and minimally formatted
interpretation elements from each knowledgebase without using any
harmonization routines. We selected the set of unique elements for each resource
and calculated the overlap across the union of those sets (Supplementary Table
3). We then repeated this procedure for harmonized elements and compared total
element count and percentage overlap between harmonized and nonharmonized
elements. Calculations for the specific fields of that table are provided in the
Supplementary Note.
Project GENIE. GENIE data were downloaded from the v.3.0.0 data release
available at: https://www.synapse.org/#!Synapse:syn7222066/files/. Variants
were extracted from ‘data_mutations_extended.txt’, and clinical data from ‘data_
clinical_sample.txt’. Variants were filtered on predicted consequence of medium
or high impact. This classification was based upon the VEP consequence table
(http://useast.ensembl.org/info/genome/variation/prediction/predicted_data.
html#consequences) and resulted in exclusion of variants classified as Silent,
3′Flank, 3′UTR, 5′Flank, 5′UTR, Intron or Splice_Region. Patients without any
variants after filtering were included in all calculations. Oncotree cross-references
were obtained from their API at http://oncotree.mskcc.org/api/tumorTypes
(data version, oncotree_2018_05_01) and cross-references were then mapped
to DO terms where they matched. In cases where one-to-many mappings
occurred, manual review of those mappings was performed to select the most
appropriate mapping.
Variant intersection search. Variant coordinates were used to search genomic
features via coordinate intersection. A complete intersection of query and target
is considered a ‘positional match’, or a more specific ‘exact match’ if the alternate
alleles also match. A ‘focal match’ is reported if the intersection fraction is less than
complete, but over 10% overlapping (reciprocally). A ‘regional match’ is reported if
there is any intersection, but the match is of no other type (Extended Data Fig. 4a).
Disease TopNode search. Disease searching returns a distance of the number
of ancestor or descendant TopNode terms between the queried disease and the
matching target (see Supplementary Note for more on TopNode terms). Two
diseases sharing a TopNode term (for example, DOID:3008, invasive ductal
carcinoma, and its parent term DOID:3007, breast ductal carcinoma, are both
members of DOID:1612, breast cancer) would have a distance of 0. However, if
two diseases share a TopNode term but do not have a direct lineage, they are not
a match. For example, DOID:0050938, ‘breast lobular carcinoma’, does not match
to DOID:3007, ‘breast ductal carcinoma’, even though they share a TopNode term
(DOID:1612, ‘breast cancer’), as they are sibling concepts and do not have an
ancestor/descendant relationship (Extended Data Fig. 4b).
Enrichment testing for GENIE Oncotree diseases that map to DO TopNode
was performed by comparing the count of a given disease term across the GENIE
patients, and then splitting these counts into two groups: those diseases that
mapped to DO in our analysis, and those that did not. This set of counts was
ranked and compared by group using the Mann–Whitney U-test. The sets of
counts (as well as the statistical test) may be found in cell 208 of the analysis
notebook accompanying this study.
Gene intersection search. To assess cohort interpretability (Extended Data Fig. 6)
when considering only matching a variant to a gene, we used the assigned gene
symbols for each GENIE variant and compared them to interpretation gene
symbols. Patients with at least one variant matching an interpretation gene symbol
were considered a match. Matches were subsequently filtered by broad disease
matching and by interpretation tier; no adjustment was made to the evidence level
and tier to account for this imprecise aggregation strategy.
ElasticSearch API and web front end. Collectors create ‘Association’ documents
segmented by the source field. Documents are posted to an ElasticSearch v.6.0
instance provisioned by AWS elasticsearch service.
On top of ElasticSearch, we built web services using the Flask web framework.
The search.cancervariants.org endpoint provides two simple REST-based
web services: an association query service and a GA4GH beacon service. The
association query service allows users to query for evidence using any combination
of keywords, while the beacon service provisions G2P associations into the
GA4GH beacon network (beacon-network.org) enabling retrieval of associations
on the basis of genomic location. OpenAPI (swagger) documentation is provided
to accelerate development and provide API integration scaffolding. Client
applications can use the API to create higher level sets of queries driven by cohort
allele sets (for example, MAF/VCF files) with varying genomic resolutions and
disease/drug combinations. The API server and nginx proxy are described by
Docker configurations and deployed colocated within a t2.micro instance.
The user interface is a customized Kibana dashboard that enhances Lucenebased full-text search of associations with interactive aggregation heat maps,
Nature Genetics | www.nature.com/naturegenetics
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tables and other components. The API documentation is available at: search.
cancervariants.org/api/v1/ui/.
Reporting Summary. Further information on research design is available in the
Nature Research Reporting Summary linked to this article.

Data availability

Analyzed harmonized data from the aggregated knowledgebases are available for
bulk download at https://s3-us-west-2.amazonaws.com/g2p-0.10/index.html.
Data are made available according to the data sharing principles and data sharing
agreement provided by the VICC (cancervariants.org/join). In accordance with
these principles, all content is available for academic research. The CIViC, CGI
Biomarkers and PMKB knowledgebases provide content with no restrictions
on reuse; however, commercial use of content from other knowledgebases is
restricted—see individual knowledgebases for current content licensing.
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Extended Data Fig. 1 | Harvesting and harmonizing records. Harvested interpretation records (left column) from each knowledgebase vary in structure,
a consequence of how they are represented and exported by their parent knowledgebase. Knowledgebase-specific rules are written to select data
from harvested records for harmonization across a suite of element-specific harmonizers (center column). Colors represent different elements of an
interpretation, which are each harmonized independently: genes (green), variants (cyan), diseases (red), drugs (purple), and evidence (yellow). Outputs
from these harmonizers are assembled into normalized records (right column).
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Extended Data Fig. 2 | Knowledgebase overlap. a, Upset plot of publications supporting clinical interpretations of variants. The overwhelming majority of
publications are observed in only 1 of 6 resources. b, Upset plot of genes described by clinical interpretations of variants. Compared to other interpretation
elements, genes are much more commonly shared between resources.
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Extended Data Fig. 3 | Knowledgebase disease enrichment. Relative distribution of interpretations describing diseases across the VICC resources. Several
resources are strongly enriched for one or more diseases compared to the entire dataset (see related Supplementary Table 8).
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Extended Data Fig. 4 | Search strategies. a, A variant intersection search strategy. Variants that match at position and allele are referred to as “exact”
(blue box), variants matching at position only as “positional” (green box), variants that largely (but not completely) intersect are considered “focal”
(orange box), and variants that overlap only a small amount are considered “regional” (red box). The left column shows matched results for a query
(search box, top), based on the intersection of coordinates in the right column. b, TopNode disease search strategy. Shown are a subset of disease nodes
that all map to the parent TopNode DOID:1612, ‘Breast Cancer’. A query for DOID:3007 would return 44 interpretations (blue) from the queried term, its
direct ancestors (DOID:3459, ‘Breast Carcinoma’ and DOID:1612, ‘Breast Cancer’) and descendants (DOID:3008, ‘invasive ductal carcinoma’), but no
interpretations (red) from indirectly related terms (DOID:0050938, ‘breast lobular carcinoma’ and DOID:3457, ‘invasive lobular carcinoma’).
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Extended Data Fig. 5 | Commonality of observed mutations and their interpretations. Interpretation count (x-axis) by number of queries (y-axis). Focal
(yellow) and positional (green) searches provide a benefit to interpretability over exact matching. Notably, several high interpretation spikes are observed,
due to variants that have both a large number of interpretations and are often observed in the GENIE cohort. These include KRAS G12 mutations, BRAF
V600E, and several mutations in PIK3CA.
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Extended Data Fig. 6 | Gene intersection search. Percentage of Project GENIE cohort with at least one interpretation from the indicated knowledgebase
that matches patient variant genes (left group), patient variant genes and disease (center group), or patient variant genes, disease, and a Tier I evidence
level (right group). This very broad match strategy is incompatible with the ASCO/AMP/CAP evidence guidelines.
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AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted
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Software and code
Policy information about availability of computer code
Data collection

Exact code for harvesting and harmonizing each of the VICC knowledgebases may be found online at https://github.com/ohsu-comp-bio/
g2p-aggregator. The cancer biomarker database from CGI was harvested from the cgi_biomarkers_per_variant.tsv file from the
biomarkers download at https://www.cancergenomeinterpreter.org/data/cgi_biomarkers_latest.zip. CIViC content was harvested via the
gene and variant API endpoints documented online at http://griffithlab.org/civic-api-docs/. JAX-CKB content of the publically available 86
genes were harvested from an unpublished API endpoint (harvester code online at https://github.com/ohsu-comp-bio/g2p-aggregator/
blob/v0.10/harvester/jax.py#L145-L147). MolecularMatch content was harvested via an authorized API key for use in the aggregated
knowledgebase (harvester code online at https://github.com/ohsu-comp-bio/g2p-aggregator/blob/v0.10/harvester/molecularmatch.py).
OncoKB content was harvested via a combination of the levels, genes, variants, and variants/lookup API endpoints documented online at:
http://oncokb.org/#/dataAccess. PMKB content was provided as a JSON file by the knowledgebase, which we are hosting online at:
https://s3-us-west-2.amazonaws.com/g2p-0.7/unprocessed-files/pmkb_interpretations.json
Gene symbols were matched to the table of gene symbols from HGNC, hosted at the European Bioinformatics Institute (EBI): ftp://
ftp.ebi.ac.uk/pub/databases/genenames/new/json/non_alt_loci_set.json. This table was used to construct an “Aliases” table comprised
of retired and alternate symbols for secondary lookup if the interpretation gene symbol was not found among the primary gene symbols
from HGNC. If an alias used by a knowledgebase was shared between two genes, omitted by the knowledgebase, or failed to match
either the primary or alias table, the gene was omitted from the normalized gene field.
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Variants harvested from each knowledgebase were first evaluated for attributes specifying a precise genomic location, such as
chromosome, start and end coordinates, variant allele, and an identifiable reference sequence. Variant names were queried against the
Catalog of Somatic Mutations in Cancer (COSMIC) v81 to infer these attributes in knowledgebases that did not provide them. Custom
rules were written to transform some types of variants without clear coordinates (e.g. amplifications) into gene coordinates. All variants
were then assembled into HGVS strings and submitted to the ClinGen Allele Registry (http://reg.clinicalgenome.org) to obtain distinct,
cross-assembly allele identifiers, if available.
Diseases were matched to the Disease Ontology (DO), through lookup with the European Bioinformatics Institute (EBI) Ontology Lookup
Service (OLS), unless a pre-existing ontology term for a different ontology existed (98.7% of interpretations map to DO). We downloaded

1

Drug names were first queried against the biothings API for harmonization (http://c.biothings.io/v1/query) and if not found were
subsequently queried against the PubChem Compounds (https://pubchem.ncbi.nlm.nih.gov/rest/pug/compound/), PubChem Substances
(https://pubchem.ncbi.nlm.nih.gov/rest/pug/substance/), and ChEMBL (https://www.ebi.ac.uk/chembl/api/data/chembl_id_lookup/
search) web services.
GENIE data were downloaded from the 3.0.0 data release available online at: https://www.synapse.org/#!Synapse:syn7222066/files/.
Variants were extracted from “data_mutations_extended.txt”, and clinical data from “data_clinical_sample.txt”. Variants were filtered on
predicted consequence of medium or high impact. This classification was based upon the VEP consequence table (http://
useast.ensembl.org/info/genome/variation/prediction/predicted_data.html#consequences) and resulted in exclusion of variants
classified as Silent, 3’Flank, 3’UTR, 5’Flank, 5’UTR, Intron, or Splice_Region. Patients without any variants after filtering were included in
all calculations. Oncotree xrefs were obtained from their API at http://oncotree.mskcc.org/api/tumorTypes (data version
oncotree_2018_05_01), and xrefs were then mapped to DO terms where they matched. In cases where 1-to-many mappings occurred,
manual review of those mappings was performed to select the most appropriate mapping.
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the March 2018 release of the TopNode terms from https://github.com/DiseaseOntology/HumanDiseaseOntology/blob/master/src/
ontology/subsets/TopNodes_DOcancerslim.json and mapped our interpretation diseases to this list, assigning each disease to its nearest
TopNode ancestor (Table S4). We assigned remaining interpretation diseases to the non-specific term of DOID:162 - Cancer if the disease
was a descendent of this term, but not a descendant of one of the TopNode terms.

Data analysis was central to this work, and described throughout the manuscript. All custom software used to generate and display these
findings are publicly available online at github.com/ohsu-comp-bio/g2p-aggregator (website) and git.io/vicckb (python interface and
analysis notebook).

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors/reviewers.
We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.
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All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability
Analyzed harmonized data from the aggregated knowledgebases are available for bulk download online at https://s3-us-west-2.amazonaws.com/g2p-0.10/
index.html. Data are made available according to the data sharing principles and data sharing agreement provided by the VICC (online at: cancervariants.org/join).
In accordance with these principles, all content is available for academic research.
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A set of 12,856 aggregate interpretations covering 3,437 unique variants in 415 genes, 357 diseases, and 791 drugs were aggregated and
harmonized from six publicly available sources. GENIE data were downloaded from the 3.0.0 data release available online at: https://
www.synapse.org/#!Synapse:syn7222066/files/. We collected 237,175 moderate or high impact variants from
“data_mutations_extended.txt” and clinical data of all 38,207 patients from “data_clinical_sample.txt”.

Data exclusions

No collected data was excluded from the study.

Replication

All experiments can be reproduced by cloning the VICCkb repository (git.io/vicckb) through the shared Jupyter analysis workbook
(analysis.ipynb).

Randomization

Content from each knowledgebase was generated independently and without coordination.

Blinding

The statistical analyses of this study were blind to the source knowledgebase, except for cases where the analysis was specifically describing
characteristics of each individual knowledgebases (e.g. Figure S3, Table S8).
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